PROKERA® biologic corneal bandage devices are used by eye doctors around the world to heal and treat ocular conditions such as keratitis, moderate to severe dry eye disease, recurrent corneal erosions, filamentary keratitis, persistent epithelial defects, neurotrophic corneas, herpetic ulcers, and many other ocular surface diseases such as chemical burns and Stevens-Johnson syndrome.
Add PROKERA® to your treatment strategy for keratitis and other ocular surface diseases.
To learn more about PROKERA® Advantage, fill out the form to download our reference guide.
PROKERA® biologic corneal bandage devices are trusted by eye doctors around the world to achieve better patient outcomes. 93% of patients with moderate-to-severe dry eye disease reported improvement after one PROKERA treatment.6 It can be easily placed during a regular office visit or used with surgical interventions.
Early intervention with PROKERA® rapidly restores the cornea’s own healing capabilities, reducing inflammation, improving corneal health, and optimizing long-term outcomes.
PROKERA® contains the only cryopreserved amniotic membrane that is FDA-cleared and has demonstrated effectiveness in reducing harmful inflammation1,2, minimizing scarring2,3 and achieving corneal clarity1.
Neel Desai, MD, discusses the use of bypassing steroids in favor of the anti-inflammatory, anti-scarring properties in the biologic corneal bandage that restores the ocular surface without compromising the epithelial healing process.”
Robert Mack, MD, discusses a new treatment option for recurrent corneal erosion, a common ocular disorder. PROKERA® can be used to restore corneal integrity, regain epithelial attachments, and prevent recurrence.
W. Barry Lee, MD recounts how a herpes simplex infection required a corneal transplant which healed in a few short days, instead of the expected weeks, through the use of a biologic corneal bandage.
1 Desai NR. A comparison of cryopreserved amniotic membrane and bandage
contact lens in their ability to provide high-quality healing after superficial keractectomy. Rev Ophthalmol. September 2014:1-6.
2 John T, Tighe S, Sheha H, et al. Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. J Ophthalmol. 2017:6404918 (Epub).
3 Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of PROKERA in the management of ocular surface and orbital disorders. Eye Contact Lens. 2009;35(4):172-175.
4 Cheng AM, Zhao D, Chen R, et al. Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. Ocul Surf. 2016;14(1):56-63.
5 Rumpakis J. Amniotic membranes—the perfect cover. Rev Ophthalmol. April 2016:49-54.
6 Data on file, Bio-Tissue.
Bio-Tissue, Inc. will use reasonable efforts to include accurate and up-to-date information on this Website but makes no warranties or representations of any kind as to its accuracy, currency, or completeness.
The contents of this web site are protected by applicable copyright laws. No permission is granted to copy, distribute, modify, post or frame any text, graphics, video, audio, software code, or user interface design or logos.
The information contained on this website is for general information and educational purposes only, and is not intended to diagnose, treat, or cure any medical conditions. Please consult with your Physician for medical advice.
Bio-Tissue, Inc. and its affiliates furnish this allograft product without any express or implied warranties. All statements or descriptions are informational only and are not to be interpreted or implied as a warranty of the allograft product. Bio-Tissue, Inc. and its affiliates make no guarantee regarding the biological characteristics of this product. The end user shall be held responsible for determining the appropriate application and usage of this product.